Tenaya Therapeutics Receives Nasdaq Delisting Notice, Expands Equity Incentive Plan

summarizeSummary

Tenaya Therapeutics received a Nasdaq delisting notice for failing to meet the minimum bid price, triggering a 180-day compliance period, and also increased its equity incentive plan shares.

check_boxKey Events

• Nasdaq Minimum Bid Price Deficiency

  The company received a notice from Nasdaq on January 28, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.

• 180-Day Compliance Period Initiated

  Tenaya Therapeutics has until July 27, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days.

• Equity Incentive Plan Expansion

  The Board approved an amendment to the 2024 Inducement Equity Incentive Plan, increasing the shares reserved for issuance by an additional 2,161,000 shares, bringing the total to 3,361,000 shares.

auto_awesomeAnalysis

Tenaya Therapeutics, Inc. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, initiating a 180-calendar day compliance period until July 27, 2026. This is a critical event, as failure to regain compliance could lead to delisting from the Nasdaq Global Select Market, significantly impacting the company's market visibility and investor confidence. Concurrently, the Board approved an amendment to the 2024 Inducement Equity Incentive Plan, increasing the shares reserved for issuance by an additional 2,161,000 shares. While intended to attract new talent, this represents a notable potential dilution at a time when the company faces significant listing challenges, adding to investor concerns.